NCT06264180: An ongoing trial by Replimune Inc.
This trial is ongoing. It must report results 4 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06264180 |
|---|---|
| Title | Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3] |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 11, 2024 |
| Completion date | Jan. 1, 2029 |
| Required reporting date | Jan. 1, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |